PCLO.V - PharmaCielo Ltd.
| Previous Close | 0.6900 |
| Open | 0.6700 |
| Bid | 0.6500 x 0 |
| Ask | 0.6900 x 0 |
| Day's Range | 0.6400 - 0.7000 |
| 52 Week Range | 0.5000 - 6.1000 |
| Volume | 261,565 |
| Avg. Volume | 154,240 |
| Market Cap | 81.604M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3410 |
| Earnings Date | Sep. 01, 2020 - Sep. 11, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.85 |
CNW GroupPharmaCielo Receives Colombian Government Authorization for 10 Tonnes of High-THC Cultivation and Extract Production for Export
TORONTO and RIONEGRO, Colombia , July 8, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (PCLO.V) (PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced today that the Colombian government granted the Company authorization for the 2020 commercial cultivation, production and export of high-THC medicinal cannabis extracts, in fulfilment of existing sales agreements. The commercial quotas obtained from the ministries of Justice and Health, enable the Company to immediately begin cultivation and processing of 10 tonnes of THC-dominant dry flower.
CNW GroupPharmaCielo Ltd. Closes $4.6 Million Bought Deal Offering
TORONTO , July 3, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (PCLOF) is pleased to announce that it has closed its previously announced "bought deal" offering (the "Offering") of common shares conducted by a syndicate of underwriters, co-led by Cormark Securities Inc. and Stifel GMP (collectively, the "Underwriters"). The Company issued 6,388,940 common shares at a price of $0.72 per common share (the "Offering Price") for aggregate gross proceeds of $4,600,036.80 , including proceeds from the exercise in full of the Underwriters' over-allotment option to purchase 833,340 additional common shares.
CNW GroupPharmaCielo Ltd. Files Final Prospectus for $4 Million Bought Deal Offering
TORONTO, June 29, 2020 /CNW/ - PharmaCielo Ltd. (the "Company" or "PharmaCielo") (TSXV:PCLO.V - News) (OTCQX:PCLOF - News) is pleased to announce that it has filed a (final) short form prospectus with the securities regulatory authorities in British Columbia, Alberta, Ontario and Quebec in connection with its previously announced $4 million "bought deal" offering of common shares (the "Offering"), co-led by Cormark Securities Inc. and Stifel GMP. The Offering is expected to close on or about July 3, 2020 and is subject to regulatory approval including that of the TSX Venture Exchange. The net proceeds of the Offering will be used for non-operational payroll expenses of PharmaCielo Colombia S.A.S. ("PharmaCielo Colombia"), non-operational payroll taxes of PharmaCielo Colombia, purchase of ethanol to be used for extraction purposes and other working capital and general corporate purposes.
- CNW Group
PharmaCielo Ltd. Announces $4,000,000 Bought Deal Public Offering
PharmaCielo Ltd. Announces $4,000,000 Bought Deal Public Offering
- Simply Wall St.
Analysts Have Been Trimming Their PharmaCielo Ltd. (CVE:PCLO) Price Target After Its Latest Report
Last week, you might have seen that PharmaCielo Ltd. (CVE:PCLO) released its quarterly result to the market. The early...
CNW GroupPharmaCielo Announces Financial Results for the First Quarter Ended March 31, 2020 and Provides Operational Update
Processing equipment is now on-site in Rionegro; the Company expects to be in a position to begin accepting broad spectrum commercial pre-orders by the end of Q2. TORONTO and RIONEGRO, Colombia, June 1, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced financial results for the first quarter ended March 31, 2020.
CNW GroupPharmaCielo Ltd. Obtains Final Receipt for Short Form Prospectus
TORONTO , May 15, 2020 /CNW/ - PharmaCielo Ltd. (the "Company" or "PharmaCielo") (PCLO.V) (PCLOF) is pleased to announce today that it has obtained a receipt for the Company's (final) short form prospectus dated May 15, 2020 (the "Prospectus"), filed with the securities regulatory authorities in the provinces of British Columbia , Ontario , and Québec. The Prospectus qualifies the distribution of 12,578,002 common shares (the "Special Warrant Shares") of the Company issuable upon the exercise or deemed exercise of 12,578,002 previously issued special warrants (the "Special Warrants"), including 12,428,002 Special Warrants issued pursuant to a best effort private placement conducted by a syndicate of agents led by Cormark Securities Inc., Stifel GMP and Echelon Wealth Partners Inc.
CNW GroupPharmaCielo Welcomes Dr. Claudia Jiménez to Board of Directors
TORONTO , May 12, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF) is pleased to welcome Dr. Claudia Jiménez (Ph.D.) to its board of directors. Dr. Jiménez's appointment is effective June 1, 2020 .
CNW GroupPharmaCielo Adds Experienced Senior Leader to Executive Team
TORONTO, May 4, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF), is pleased to announce the appointment of Mr. Henning von Koss to the new role of President, overseeing all day-to-day operations and project development with immediate effect. Mr. von Koss will remain on the board of directors of PharmaCielo. Mr. von Koss has spent his career managing operations primarily in Latin America and Europe, with experience in several countries, including Brazil, Colombia, Venezuela, Germany and Poland.
- Simply Wall St.
These Analysts Just Made An Downgrade To Their PharmaCielo Ltd. (CVE:PCLO) EPS Forecasts
One thing we could say about the analysts on PharmaCielo Ltd. (CVE:PCLO) - they aren't optimistic, having just made a...
- Simply Wall St.
Analysts Have Lowered Expectations For PharmaCielo Ltd. (CVE:PCLO) After Its Latest Results
The analysts might have been a bit too bullish on PharmaCielo Ltd. (CVE:PCLO), given that the company fell short of...
- Newsfile
TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against PharmaCielo Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - April 30, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against PharmaCielo Ltd. (OTCQX: PCLOF) ("PharmaCielo" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 21, 2019 and March 2, 2020, inclusive (the ...
- CNW Group
PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2019
$13.7 million in cash and cash equivalents at December 31, 2019; Subsequent to the end of the quarter, the Company closed a private placement financing for gross proceeds of approximately $8 million. TORONTO and RIONEGRO, Colombia, April 30, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced financial results for the fourth quarter and year ended December 31, 2019. Because of these efforts, as well as additional progress made early this year, PharmaCielo is well-positioned to achieve its 2020 goals despite COVID-19 related disruptions," said David Attard, Chief Executive Officer of PharmaCielo Ltd. "Our objectives this year are straightforward and achievable.
CNW GroupPharmaCielo Provides Details for Fourth Quarter and Year-End 2019 Results Conference Call
TORONTO , April 29, 2020 /CNW/ - PharmaCielo Ltd. (" PharmaCielo " or the " Company ") ( TSXV:PCLO, OTCQX:PCLOF ), the Canadian parent of Colombia's premier cultivator and producer ...
- Newsfile
PharmaCielo Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in PharmaCielo Ltd. to Contact the Firm
New York, New York--(Newsfile Corp. - April 29, 2020) - Faruqi, LLP, a leading national securities law firm, reminds investors in PharmaCielo Ltd. (OTCQX: PCLOF) ("PharmaCielo" or the "Company") of the May 5, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logoIf you invested in PharmaCielo stock or options between June 21, 2019 and March 2, ...
- Newsfile
PharmaCielo Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in PharmaCielo Ltd. to Contact the Firm
New York, New York--(Newsfile Corp. - April 24, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in PharmaCielo Ltd. (OTCQX: PCLOF) ("PharmaCielo" or the "Company") of the May 5, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logoIf you invested in PharmaCielo stock or options between June 21, 2019 and ...
- Simply Wall St.
When Can We Expect A Profit From PharmaCielo Ltd. (CVE:PCLO)?
PharmaCielo Ltd.'s (CVE:PCLO): PharmaCielo Ltd., through its subsidiary, PharmaCielo Colombia Holdings S.A.S...
CNW GroupPharmaCielo Ltd. Announces Closing of Previously Announced $8 Million Private Placement Financing
TORONTO, April 15, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF) announced today that it has closed its previously announced "best efforts" private placement financing of 12,428,002 special warrants of the Company (the "Special Warrants") (inclusive of the Broker Special Warrants (as defined herein)) at $0.65 (the "Offering Price") per Special Warrant for aggregate gross proceeds of approximately $8 million (the "Offering"). The Offering was conducted by a syndicate of agents led by Cormark Securities Inc., Stifel GMP and Echelon Wealth Partners Inc. (collectively, the "Agents").
- Business Wire
PCLOF LOSS NOTICE: ROSEN, A TOP FIRM, Reminds PharmaCielo Ltd. Investors with Large Losses of the May 5th Deadline in Class Action Seeking Recovery of Investor Losses - PCLOF
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PharmaCielo Ltd. (OTC: PCLOF) between June 21, 2019 and March 2, 2020, inclusive (the "Class Period"), of the important May 5, 2020 lead plaintiff deadline in the securities class action filed by the firm. The lawsuit seeks to recover damages for PharmaCielo investors under the federal securities laws.
- Business Wire
Shareholder Alert: Robbins LLP Announces It Is Investigating PharmaCielo Ltd. (PCLOF) for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that it is investigating PharmaCielo Ltd. (OTC: PCLOF) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. PharmaCielo, through its subsidiary, PharmaCielo Colombia Holdings S.A.S., cultivates, processes, produces, and supplies medical-grade cannabis oil extracts and related products in Colombia and internationally.
CNW GroupPharmaCielo Ltd. Prices $8 Million Offering; Closing Scheduled for April 14
TORONTO, April 6, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF) announced today that further to its April 1 release, it has received subscriptions and subscription commitments in excess of CAD$8 million for its previously announced best efforts private placement offering (the "Offering") of special warrants ("Special Warrants"). The Offering has been priced in the context of the market with each Special Warrant now being offered at a price of CAD$0.65 per Special Warrant. The Company also announced today that the $5 million lead subscriber of the Offering has agreed to lower its earlier condition for the minimum size of the Offering to gross proceeds of CAD$8 million.
- CNW Group
PharmaCielo Ltd. Announces Best Efforts Private Placement Offering
TORONTO, April 1, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF) is pleased to announce that, subject to all necessary approvals, it is undertaking a "best efforts" private placement offering of special warrants of the Company (the "Special Warrants") at a price of $0.75 (the "Offering Price") per Special Warrant (the "Offering"). The Company has received interest from multiple investors for the Offering, including a subscription agreement for Special Warrants totaling $5 million, conditional on aggregate proceeds committed to the Company pursuant to the Offering of $9 million.
- Business Wire
Shareholder Alert: Robbins LLP Reminds Investors PharmaCielo Ltd. (PCLOF) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP reminds investors that a purchaser of PharmaCielo Ltd. (OTC: PCLOF) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between June 21, 2019 and March 2, 2020. PharmaCielo, through its subsidiary, PharmaCielo Colombia Holdings S.A.S., cultivates, processes, produces, and supplies medical-grade cannabis oil extracts and related products in Colombia and internationally.
CNW GroupPharmaCielo Independent Investigation Concludes Short-seller Report Contains Accusations and Claims based on Faulty Interpretation of Events and Information
TORONTO, March 23, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF), has issued the Company's detailed response to a short seller report that contains incorrect analysis of a broad range of events and information on the Company's operations, land and property acquisitions, marketing and distribution contracts, and claims about the founders and directors, among others. The Company referenced the misleading short seller report in its press release dated March 3, 2020. On March 3, PharmaCielo's board of directors appointed Doug Bache, Audit Committee Chair, as lead independent director (the "Lead Director") to undertake an independent investigation of the allegations and claims made by a short seller against the Company and its founders.
- Business Wire
PCLOF INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Alerts Investors of Class Action Against PharmaCielo Ltd. and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against PharmaCielo Ltd. ("PharmaCielo" or "the Company") (OTCMKT: PCLOF) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired PharmaCielo securities between June 21, 2019 and March 2, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/pclof.
